Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 1

Conditions

Neoplasm Metastasis 3Melanoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Virus Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pain 1Neuroectodermal Tumors 1Neuroblastoma 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Insulin-Like Growth Factor I, Resistance To 1Humoral Hypercalcemia Of Malignancy 1Gliosarcoma 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Disease 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Melanoma × Antibodies, Monoclonal × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00356460 2014-03-19

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Sanofi

Phase 1 Completed
29 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡